U.S. Government Engages Dx Firms For Rapid, Field-Based Ebola Test
This article was originally published in The Gray Sheet
Executive Summary
Multiple companies are receiving funding or are in discussions with federal agencies about development of rapid assays for Ebola that can be used by patients and health care workers in the field, a top official at the National Institute of Allergy and Infectious Diseases told "The Gray Sheet."
You may also be interested in...
Ebola Response Funds From Congress, Gates Group Could Hasten Rapid Test Development
The House FY 2015 federal spending continuing resolution would direct HHS and CDC to spend $88 million to deliver Ebola countermeasures, while Gates Foundation gives $50 million to the cause.
The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.
Syngene COO On Delivering Cost Gains For mRNA Products
Syngene’s COO, Mahesh Bhalgat, tells Scrip the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.